Qijia Yu

Qijia Yu

Auto-generated profile, based on publicly available information

Qijia Yu

Division of Genomic Stability and DNA Repair, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SPSeth Parker
Seth Parker
CACaroline R. Amendola
Caroline R. Amendola
KHKate E.R. Hollinshead
Kate E.R. Hollinshead
QYQijia Yu
Qijia Yu
KYKeisuke Yamamoto
Keisuke Yamamoto
AKAlec C. Kimmelman
Alec C. Kimmelman
Pancreatic ductal adenocarcinoma (PDAC) evolves a complex microenvironment comprised of multiple cell types, including pancreatic stellate cells (PSC). Previous studies have demonstrated that stromal supply of alanine, lipids, and nucleotides supports the metabolism, growth, and therapeutic resistance of PDAC. Here we demonstrate that alanine cross-talk between PSCs and PDAC is orchestrated by the utilization of specific transporters. PSCs utilize SLC1A4 and other transporters to rapidly exchange and maintain environmental alanine concentrations. Moreover, PDAC cells upregulate SLC38A2 to supply their increased alanine demand. Cells lacking SLC38A2 fail to concentrate intracellular alanine and undergo a profound metabolic crisis resulting in markedly impaired tumor growth. Our results demonstrate that stromal–cancer metabolic niches can form through differential transporter expression, creating unique therapeutic opportunities to target metabolic demands of cancer. Significance: This work identifies critical neutral amino acid transporters involved in channeling alanine between pancreatic stellate and PDAC cells. Targeting PDAC-specific alanine uptake results in a metabolic crisis impairing metabolism, proliferation, and tumor growth. PDAC cells specifically activate and require SLC38A2 to fuel their alanine demands that may be exploited therapeutically. This article is highlighted in the In This Issue feature, p. 890

1 September 2011 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
SWShu-Ya Wang
Shu-Ya Wang
QYQi-Jia Yu
Qi-Jia Yu
RZRudian Zhang
Rudian Zhang
BLBo Liu
Bo Liu

1 March 2020 in Cell Reports
Verified
Journal Article
Open access
NCNaiara Santana Codina
Naiara Santana Codina
ACAmrita Singh Chandhoke
Amrita Singh Chandhoke
QYQijia Yu
Qijia Yu
BMBeata Małachowska
Beata Małachowska
MKMiljan Kuljanin
Miljan Kuljanin
JMJoe Mancias
Joe Mancias
Covalent inhibitors of the KRASG12C oncoprotein have recently been developed and are being evaluated in clinical trials. Resistance to targeted therapies is common and may limit long-term efficacy of KRAS inhibitors (KRASi). To identify pathways of adaptation to KRASi and predict drug combinations that circumvent resistance, we use mass-spectrometry-based quantitative temporal proteomics to profile the proteomic response to KRASi in pancreatic and lung cancer 2D and 3D cellular models. We quantify 10,805 proteins, representing the most comprehensive KRASi proteome (https://manciaslab.shinyapps.io/KRASi/). Our data reveal common mechanisms of acute and long-term response between KRASG12C-driven tumors. Based on these proteomic data, we identify potent combinations of KRASi with phosphatidylinositol 3-kinase (PI3K), HSP90, CDK4/6, and SHP2 inhibitors, in some instances converting a cytostatic response to KRASi monotherapy to a cytotoxic response to combination treatment. Overall, using quantitative temporal proteomics, we comprehensively characterize adaptations to KRASi and identify combinatorial regimens with potential therapeutic utility.

1 March 2011 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SWShu-Ya Wang
Shu-Ya Wang
QYQi-Jia Yu
Qi-Jia Yu
JBJin-Ku Bao
Jin-Ku Bao
BLBo Liu
Bo Liu

22 February 2019 in Analytical Chemistry
Verified
Journal Article
Closed access
JMJohn Patrick Murphy
John Patrick Murphy
QYQijia Yu
Qijia Yu
PKPrathyusha Konda
Prathyusha Konda
JPJoao A. Paulo
Joao A. Paulo
MJMark P. Jedrychowski
Mark P. Jedrychowski
SGShashi Gujar
Shashi Gujar

7 July 2011 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
QYQi-Jia Yu
Qi-Jia Yu
ZLZi-Yue Li
Zi-Yue Li
SYShun Yao
Shun Yao
MMMiao Ming
Miao Ming
SWShu-Ya Wang
Shu-Ya Wang
JBJin-Ku Bao
Jin-Ku Bao